Recombinant Zoster Vaccine (Shingrix): a nex gun for Rheumatologist
Herpes Zoster, or as commonly known shingles, is a debilitating painful rash occurring at any age in anyone caused by reactivation of the varicella zoster virus (VZV). The lifetime risk of HZ in the general population is around 30% HZ incidence increases with age and is estimated that 90% of adults...
Saved in:
Main Authors: | D. Marotto (Author), P. Sarzi Puttini (Author), A. Riva (Author) |
---|---|
Format: | Book |
Published: |
Verduci Editore,
2022-03-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Position paper of the Italian College of Rheumatologists (CReI) on herpes zoster vaccination
by: D. Marotto, et al.
Published: (2022) -
Biosimilars: New guns for the treatment of rheumatological patients?
by: Daniela Marotto, et al.
Published: (2019) -
A critical appraisal of 'Shingrix', a novel herpes zoster subunit vaccine (HZ/Su or GSK1437173A) for varicella zoster virus
by: Tehmina Bharucha, et al.
Published: (2017) -
Delayed inflammatory reaction to hyaluronic acid filler following Shingrix and Fluzone vaccines treated with lisinopril
by: Jacqueline Witt, MD, et al.
Published: (2022) -
Cost-effectiveness of the recombinant zoster vaccine (RZV) against herpes zoster: An updated critical review
by: Nikolaos Giannelos, et al.
Published: (2023)